---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-233934"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2023-09-13T23:59:59+00:00"
generated_at: "2026-06-10T19:29:07.401883+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics starts Phase 3 trial for epetraborole in refractory MAC lung disease

## Summary
- Phase 2 enrollment completed with 80 patients; topline Phase 2 data expected summer 2024.
- Phase 3 part launched with over 100 sites in U.S., Japan, South Korea, Australia; plans to enroll ~230 patients.
- Epetraborole is an oral, once-daily drug; FDA granted Fast Track, QIDP, and orphan drug designations.
- No approved oral therapy currently exists for MAC lung disease.

## SEC filing metadata
- accession: 0001193125-23-233934
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2023-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312523233934/0001193125-23-233934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312523233934/d545132d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-233934
- JSON: https://secwatch.observer/filing/0001193125-23-233934.json
- Plain text: https://secwatch.observer/filing/0001193125-23-233934.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.